Skylarys

Reata CEO Warren Huff

Plano’s Reata Pharmaceuticals Launches First Product: The Rare-Disease Drug Skylarys

by | Jun 29, 2023
Reata cleared the final FDA hurdle to get its rare-disease drug Skylarys on the market, the company announced Tuesday. The drug is now available to U.S. patients who've been diagnosed with Friedreich’s ataxia—a genetic disorder that can cause progressive damage to the nervous system. The announcement marks Reata’s first drug approval since the company was founded in 2002, according to the Dallas Morning News.
MORE